CA-MAANA
5.12.2018 02:37:04 CET | Business Wire | Press release
Maana, the pioneer of digital knowledge technology, announced the expansion of its international operations with the opening of its London office. Marking the company’s fifth location since its beginnings in 2013, the UK headquarters is located at One Canada Square, an iconic building residing in Canary Wharf – a rich cultural district housing several Fortune Global 500 listed corporations.
This expansion highlights the market’s response to Maana’s solution, the Knowledge Platform, which enables industrial organizations to accelerate decision making across the enterprise, gaining operational efficiencies and resulting in considerable CAPEX and OPEX improvements.
“We are excited to be working with the industry’s top leaders - the catalysts for change - who are breaking the barriers of data and organizational silos so that their enterprises can realize the benefits of a fully digitalized infrastructure,” said Maana Founder and CEO, Babur Ozden. “From our new London office, we will support our growing customer base in Europe and have access to top talent to grow our organization.”
The London operations augment Maana’s existing presence in Palo Alto, California; Bellevue, Washington; Houston, Texas and Dhahran, Saudi Arabia and is home to Maana’s team of experts who have implemented groundbreaking business applications and solutions for companies like IBM, Cisco, Romonet and Elsevier.
“London is a critical hub for the global energy sector and a large segment of our international industrial clients,’ said Kieran O’Byrne, a Principal Customer Solutions Analyst who previously worked for IBM driving the adoption of IBM Watson technologies. “I’m happy to join Maana’s accomplished team of London-based data scientists and customer solutions team members. This marquee location will only further our recruitment activities and will help our customer’s digital transformation journeys.”
About Maana:
Maana is an award-winning digital knowledge platform provider focused on creating CAPEX and OPEX gains for industrial companies. Its unique Computational Knowledge Graph ™ de-silos knowledge from data sources and tacit expertise, to improve decision making across the enterprise. Maana’s investors include Intel Capital, GE Ventures, Chevron Technology Ventures, Saudi Aramco Energy Ventures, Shell Technology Ventures, Accenture Ventures, and China International Capital Corporation.
Maana is privately held with offices in Palo Alto, California; Bellevue, Washington; Houston, Texas, London, UK; and Dhahran, Saudi Arabia. Visit us at https://www.maana.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204006195/en/
Contact:
Linda Madden lmadden@piercom.com (713) 627-2223
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release
Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release
An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p
Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse
Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
